Published in Virulence on October 20, 2016
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
Error bars in experimental biology. J Cell Biol (2007) 5.81
Isolation and characterization of Pseudomonas aeruginosa PAO mutant that produces altered elastase. J Bacteriol (1980) 5.74
Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell (2010) 5.33
Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol (2007) 4.83
In-vitro methods for determining minimal lethal concentrations of antimicrobial agents. Am J Clin Pathol (1979) 4.66
Tackling antibiotic resistance. Nat Rev Microbiol (2011) 3.95
Simplified agar plate method for quantifying viable bacteria. Biotechniques (1997) 3.90
Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J Bacteriol (1995) 3.73
Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol (2006) 2.68
The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol Med (2004) 2.48
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07
Pseudomonas aeruginosa pyocyanin is critical for lung infection in mice. Infect Immun (2004) 2.03
Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother (1997) 1.91
Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol (2014) 1.89
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents (2015) 1.87
Phospholipase C (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization. J Bacteriol (1982) 1.78
A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res (2012) 1.70
Frontal and stealth attack strategies in microbial pathogenesis. Nature (2004) 1.69
Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect (2006) 1.68
Pili binding to asialo-GM1 on epithelial cells can mediate cytotoxicity or bacterial internalization by Pseudomonas aeruginosa. Infect Immun (1999) 1.58
Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother (2009) 1.50
Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun (1996) 1.48
Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother (1994) 1.48
Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med (2010) 1.45
Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol (2008) 1.45
Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resist Updat (2012) 1.42
Phototargeting oral black-pigmented bacteria. Antimicrob Agents Chemother (2005) 1.42
Visible 405 nm SLD light photo-destroys methicillin-resistant Staphylococcus aureus (MRSA) in vitro. Lasers Surg Med (2008) 1.38
The effect of photodynamic action on two virulence factors of gram-negative bacteria. Photochem Photobiol (2000) 1.30
Pseudomonas aeruginosa pili and flagella mediate distinct binding and signaling events at the apical and basolateral surface of airway epithelium. PLoS Pathog (2012) 1.25
Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. Anal Biochem (2001) 1.13
Attenuated virulence and biofilm formation in Staphylococcus aureus following sublethal exposure to triclosan. Antimicrob Agents Chemother (2012) 1.13
Evaluation of self-treatment of mild-to-moderate facial acne with a blue light treatment system. J Drugs Dermatol (2011) 1.11
Clinical and histological effects of blue light on normal skin. Photodermatol Photoimmunol Photomed (2010) 1.09
Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert Rev Anti Infect Ther (2012) 1.07
Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother (2012) 1.07
Lung infections after cancer chemotherapy. Lancet Oncol (2008) 1.05
Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol (1994) 1.03
Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A. PLoS One (2011) 1.03
Involvement of a phospholipase C in the hemolytic activity of a clinical strain of Pseudomonas fluorescens. BMC Microbiol (2008) 1.02
Pseudomonas aeruginosa Biofilm Infections: Community Structure, Antimicrobial Tolerance and Immune Response. J Mol Biol (2015) 0.99
Different photoresponses of Staphylococcus aureus and Pseudomonas aeruginosa to 514, 532, and 633 nm low level lasers in vitro. Curr Microbiol (2006) 0.97
Integrated circuit-based electrochemical sensor for spatially resolved detection of redox-active metabolites in biofilms. Nat Commun (2014) 0.96
Ultraviolet-C light for treatment of Candida albicans burn infection in mice. Photochem Photobiol (2011) 0.94
Pyocyanin facilitates extracellular DNA binding to Pseudomonas aeruginosa influencing cell surface properties and aggregation. PLoS One (2013) 0.94
Aspirin is an efficient inhibitor of quorum sensing, virulence and toxins in Pseudomonas aeruginosa. Microb Pathog (2014) 0.94
Multiresistant strains are as susceptible to photodynamic inactivation as their naïve counterparts: protoporphyrin IX-mediated photoinactivation reveals differences between methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains. Photomed Laser Surg (2014) 0.93
405 nm light technology for the inactivation of pathogens and its potential role for environmental disinfection and infection control. J Hosp Infect (2014) 0.93
Characterization of elastase-deficient clinical isolates of Pseudomonas aeruginosa. Infect Immun (1996) 0.92
Blue light kills Aggregatibacter actinomycetemcomitans due to its endogenous photosensitizers. Clin Oral Investig (2013) 0.89
Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients. Eur Respir J Suppl (2002) 0.89
Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model. PLoS One (2013) 0.89
Inhibitors and specificity of Pseudomonas aeruginosa LasA. J Biol Chem (1997) 0.88
Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent. BMC Microbiol (2009) 0.88
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections. J Med Chem (2016) 0.86
UVC light prophylaxis for cutaneous wound infections in mice. Antimicrob Agents Chemother (2012) 0.85
Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection. J Photochem Photobiol B (2011) 0.85
Motility assay: twitching motility. Methods Mol Biol (2014) 0.84
Antibacterial Activity of Blue Light against Nosocomial Wound Pathogens Growing Planktonically and as Mature Biofilms. Appl Environ Microbiol (2016) 0.84
Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev Anti Infect Ther (2015) 0.83
Antimicrobial photodynamic inactivation inhibits Candida albicans virulence factors and reduces in vivo pathogenicity. Antimicrob Agents Chemother (2012) 0.83
Plate-based assay for swimming motility in Pseudomonas aeruginosa. Methods Mol Biol (2014) 0.81
Cellular responses of A549 alveolar epithelial cells to serially collected Pseudomonas aeruginosa from cystic fibrosis patients at different stages of pulmonary infection. FEMS Immunol Med Microbiol (2010) 0.81
Photo-activated porphyrin in combination with antibiotics: therapies against Staphylococci. J Photochem Photobiol B (2013) 0.81
New approaches to control infections: anti-biofilm strategies against gram-negative bacteria. Chimia (Aarau) (2013) 0.80
Antimicrobial susceptibility testing of anaerobic bacteria: review, comments, and opinions. Ann Otol Rhinol Laryngol Suppl (1991) 0.79
Light regulates motility, attachment and virulence in the plant pathogen Pseudomonas syringae pv tomato DC3000. Environ Microbiol (2013) 0.79
In vitro bactericidal effects of 625, 525, and 425 nm wavelength (red, green, and blue) light-emitting diode irradiation. Photomed Laser Surg (2013) 0.79
Quenching of singlet oxygen by pyocyanin and related phenazines. Photochem Photobiol (2010) 0.78
Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: A combinatorial study with azithromycin and gentamicin. Sci Rep (2016) 0.77
Virulence of Pseudomonas aeruginosa cells surviving photodynamic treatment with toluidine blue. Curr Microbiol (2005) 0.77
Synergistic antimicrobial effect of photodynamic therapy and ciprofloxacin. J Photochem Photobiol B (2016) 0.77
Antimicrobial blue light inactivation of Pseudomonas aeruginosa by photo-excitation of endogenous porphyrins: In vitro and in vivo studies. Lasers Surg Med (2016) 0.77
Effect of Photodynamic Therapy on the Virulence Factors of Staphylococcus aureus. Front Microbiol (2016) 0.76
Fine-tuning recA expression in Staphylococcus aureus for antimicrobial photoinactivation: importance of photo-induced DNA damage in the photoinactivation mechanism. Appl Microbiol Biotechnol (2015) 0.75
Fast Selective Detection of Pyocyanin Using Cyclic Voltammetry. Sensors (Basel) (2016) 0.75